Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
Open Access
- 1 January 1994
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 93 (1), 140-146
- https://doi.org/10.1172/jci116937
Abstract
We have investigated the systemic anti-HIV antibody response in chimpanzees who were immunized with live vaccinia containing either the HIV envelope glycoprotein (gp160IIIB) or a control antigen (herpes simplex virus glycoprotein D) and then challenged with either a high dose (300,000 TCID50) or low dose (100 TCID50) of HIVIIIB. HIV was subsequently isolated from all animals, indicating failure of the vaccination to protect against HIV infection. Serum antibody responses were evaluated before immunization, at the time of challenge with HIV, and at multiple time points in the 9 mo after challenge. Immunization resulted in a more rapid rise of antibody to gp160 in both high and low dose animals. Antibodies to the V3 loop induced upon infection were unaffected by immunization. In low dose animals, neutralizing antibody rose more rapidly and to higher levels in the immunized animals as compared with the control. There was no difference in neutralizing antibodies between immunized and control chimpanzees in the high dose group. Epitope mapping of the anti-gp 160 response indicated that immunization with gp160 vaccinia induced a postinfection antibody response to a region of gp41 (amino acids 718-743) that was not immunogenic in control-vaccinated animals. These data indicate that failed vaccination with the HIV envelope can alter both the timing and epitope specificity of the subsequent anti-HIV antibody response. These studies also define the evolution and fine specificity of the antibody response during the critical period immediately postinfection.This publication has 23 references indexed in Scilit:
- Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.Journal of Clinical Investigation, 1993
- Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear CellsScience, 1992
- Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoproteinThe Lancet, 1991
- Safety and Immunogenicity of a Genetically Engineered Human Immunodeficiency Virus VaccineThe Journal of Infectious Diseases, 1991
- Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.Proceedings of the National Academy of Sciences, 1991
- The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in HumansAnnals of Internal Medicine, 1991
- Use of a New CD4-Positive HeLa Cell Clone for Direct Quantitation of Infectious Human Immunodeficiency Virus from Blood Cells of AIDS PatientsThe Journal of Infectious Diseases, 1991
- Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160Nature, 1990
- Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Proceedings of the National Academy of Sciences, 1989
- Expression of AIDS virus envelope gene in recombinant vaccinia virusesNature, 1986